Geron Corp. buy klostergang
Start price
26.06.15
/
50%
€3.58
Target price
07.12.15
€4.50
Performance (%)
29.46%
End price
07.12.15
€4.63
Summary
This prediction ended on 07.12.15 with a price of €4.63. The BUY prediction by klostergang finished with a performance of 29.46%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | 2.934% | 2.934% | 0.210% | -59.116% |
| iShares Core DAX® | 4.572% | 4.137% | 7.348% | 57.579% |
| iShares Nasdaq 100 | 1.832% | -1.638% | 33.644% | 88.081% |
| iShares Nikkei 225® | -0.289% | 2.472% | 60.448% | 76.665% |
| iShares S&P 500 | 2.229% | 0.707% | 24.129% | 66.108% |
Comments by klostergang for this prediction
In the thread Geron Corp. diskutieren
Mit JNJ-Partnerschaft und Orphan Drug der FDA gegen Krebs :
Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.